



Cite this: *Org. Biomol. Chem.*, 2015, **13**, 6059

## Selective chemical modification of DNA with alkoxy- and benzyloxyamines†

Lorina Gjonaj and Gerard Roelfes\*

Received 25th March 2015,  
Accepted 29th April 2015

DOI: 10.1039/c5ob00595g

www.rsc.org/obc

A new method for the selective chemical modification of DNA at cytosine nucleobases using alkoxy- and benzyloxyamines is presented. It is shown that in particular benzyloxyamines are effective DNA modifying agents, giving rise to almost exclusive formation of the mono addition products. By using a bifunctional derivative, that is, *p*-azidobenzyloxyamine hydrochloride, an azide moiety, which is a convenient handle for further functionalization, could be introduced into the DNA. The azido modified DNA was then further reacted in a copper(i)-monophos catalysed 1,3-dipolar cycloaddition. These results illustrate the potential of the presented method for application in site and chemo-selective modification of DNA.

## Introduction

The unique chemical and physical properties of DNA have paved the way for widespread application of this molecule far beyond its natural role as carrier of genetic information. The selective recognition of complementary nucleobases, resulting in Watson–Crick base pairing, has proven to be a very powerful tool for the assembly of complex DNA structures.<sup>1</sup> For many applications, however, additional chemical functionalities need to be introduced into the DNA. Functionalized DNAs have found applications in diverse fields such as nanotechnology, synthesis and catalysis and chemical biology, for example as DNA sensors, for electrochemical analysis,<sup>2</sup> DNA labelling,<sup>3</sup> DNA-based catalysis,<sup>4</sup> hybrid materials and drug delivery systems<sup>5</sup> and many more.

The most common method used for the preparation of functionalized DNAs involves solid phase synthesis, which is convenient for obtaining small quantities of short oligonucleotides containing novel functionalities.<sup>6</sup> Another popular approach for the preparation of functionalized DNA involves the enzymatic incorporation of modified nucleotide triphosphates (dNTPs) by DNA polymerases.<sup>7</sup>

Both these approaches have in common that they require multistep chemical synthesis of the necessary nucleotide building blocks, which is laborious and time consuming. Ideally, it would be possible to introduce a novel chemical functionality selectively in the DNA in a post-(bio)-synthetic step. The fact that DNA is built up from only 4 building blocks

that present very similar functional groups makes this a highly challenging task.

One example of such an approach is the sequence specific modification of DNA by use of DNA methyltransferase.<sup>8</sup> While this method has enormous potential, it again relies on synthetic nucleotides, that are, *S*-adenosyl methionine derivatives.<sup>9</sup>

A limited number of methods for the selective chemical modification of DNA have been developed. This includes bio-orthogonal labelling of 5-hydroxymethylcytosine,<sup>10</sup> selective DNA G-quadruplex alkylating agents,<sup>11</sup> reaction of cytosine with bisulfite followed by transamination,<sup>12</sup> selective alkylation of exocyclic amines with rhodium and copper carbenoid complexes,<sup>13</sup> and using cisplatin as a covalent anchor for catalytically active metal complexes.<sup>4a,14</sup>


Alkoxyamines are frequently used in bioconjugation reactions, also to DNA, albeit that this generally involves reactions with an introduced bio-orthogonal aldehyde moiety, resulting in oxime formation.<sup>15</sup> However, hydroxyl and methoxyamines have long been known to modify DNA selectively. This is, for example, the foundation for their use as mutagenic agents and in Maxam–Gilbert sequencing.<sup>16</sup>

Both hydroxyl- and methoxyamine react specifically and hundred times more efficiently with exposed cytosine residues compared to the other three nucleobases.<sup>17</sup> The main products of this reaction are the result of nucleophilic attack on either C4 or C6, which are the most electrophilic positions. At high concentrations of alkoxyamine, commonly the C4 substitution product A and the double addition product B are obtained as the main products (Scheme 1). The efficiency and the selectivity of the reaction are dependent on the pH, temperature and concentration.<sup>18</sup> Here we report that alkoxyamines, and in particular benzyloxyamines, are excellent reagents for the selective mono-functionalization of cytosine in DNA. Moreover, we show that by using a bifunctional benzyloxyamine derivative

Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands. E-mail: j.g.roelfes@rug.nl; http://roelfesgroup.nl

†Electronic supplementary information (ESI) available. See DOI: 10.1039/c5ob00595g





**Scheme 1** Reaction of hydroxylamine and methoxyamine with cytosine.

containing an azide moiety, further functionalization of DNA can be achieved using azide-alkyne click chemistry.

## Results and discussion

### Synthesis of alkoxyamines


The alkoxyamines hydrochloride salts **1–7** were used in this study (Fig. 1). **1**, **5** and **6** were available from commercial sources, **3** and **4** were prepared following literature procedures.<sup>19</sup>

**2** was prepared from decyl bromide (**8**) by reaction with *N*-hydroxyphtalamide in the presence of  $K_2CO_3$  giving rise to **9** (Scheme 2). This was followed by reaction with hydrazine hydrate, resulting in the free alkoxyamine **10**. Treatment of **10** with HCl [6 M] provided 1-decylhydroxylamine hydrochloride salt **2**.


Azide modified benzyloxyamine **7** was prepared using the synthetic route outlined in Scheme 3. *p*-Azido-toluene (**12**) was prepared by reacting *p*-toluidine (**11**) with  $NaNO_2/HCl$  and  $NaN_3$ . The subsequent bromination reaction was performed using NBS and AIBN, which did not result in full conversion, even after 3 days. Treatment of **13** with *N*-hydroxyphtalamide in presence of a base yielded **14**, which possessed the aminoxyl functionality. Deprotection of **14** with hydrazine hydrate furnished the free alkoxyamine, which was transformed immediately to the corresponding hydrochloride salt **7**.

### DNA modification with alkoxyamines


The optimal reaction conditions for DNA modification were investigated in the reaction of *O*-methoxyamine-HCl (**1**) with a



**Scheme 2** Synthesis of **2**. (i) *N*-Hydroxyphtalamide,  $K_2CO_3$ , DMF, overnight, 83%; (ii) hydrazine hydrate, DCM, overnight, 69%; (iii) 10 M HCl, quantitative.




**Scheme 3** Synthesis of azido modified benzyloxyamine **7**. (i)  $NaNO_2$ , HCl,  $NaN_3$ ,  $H_2O$ , 85%; (ii) NBS, AIBN, benzene, 3 days, 69%; (iii) *N*-hydroxyphtalamide,  $K_2CO_3$ , DMF, overnight, 76%; (iv) hydrazine hydrate, DCM, overnight, 56%; v. Conc. HCl, quantitative.



**Fig. 1** Alkoxyamines used in this study.

single stranded DNA pentamer with sequence dTACGT (**O1**), containing only one cytosine. This reaction gives rise to 2 possible products: the mono-substituted adduct A and double substituted product B. A first screening of conditions revealed that the shortest reaction time and optimal selectivity was achieved at pH = 4 and a reaction temperature of 50 °C (Table S1†). Next, the dependence on the concentration of **1** was determined (Table 1). The highest ratio A/B, i.e. A/B = 12, was obtained at a final concentration of **1** of 0.5 M (entry 3), but with relatively low conversions after 8 h. A longer reaction time resulted in almost full conversion, albeit accompanied by a small decrease in selectivity (entry 4). Lowering the concentration of **1** further resulted in a decrease of both the ratio A/B and the reaction rate. Therefore it was concluded that the optimal conditions to achieve both high conversion and high selectivity were pH = 4.0, 50 °C and final concentration of 0.5 M of the methoxyamine (Table 1, entry 4). The products were purified using reversed phase HPLC and their identity was confirmed by MALDI-TOF (A  $m/z$  = 1507 and B  $m/z$  = 1554, respectively).



Table 1 Optimization of the reaction of **1** with oligo **1**<sup>a</sup>


Entry	<b>1</b> (M)	Conversion <sup>b</sup> (%)	Time <sup>c</sup> (h)	Ratio A/B <sup>d</sup>
1	1.25	94	24	3
2	0.75	97	24	3
3	0.5	40	8	12
4	0.5	95	24	9
5	0.25	100	48	6
6	0.1	80	48	4.5


<sup>a</sup> All experiments were carried out in the presence of oligo **1** [100 μM], methoxyamine **1** (pH = 4 and 50 °C). <sup>b</sup> Determined by RP-HPLC. <sup>c</sup> Time after which the samples were taken. <sup>d</sup> Determined with RP-HPLC.

Having established the optimal conditions for modifying DNA with **1**, the scope of the reaction was explored using a variety of other alkoxyamines. First the alkoxyamines **2–4** were investigated. **2** contains a long alkyl chain and the DNA adduct potentially can be used for the synthesis of DNA surfactants, which have found applications in nanotechnology.<sup>20</sup> After optimization it was found that at room temperature (r.t) and at 0.45 M methoxyamine concentration gave the best result with a ratio A/B of 4 : 1 (Table S2†).

Amino modified DNAs are useful scaffolds for derivatization.<sup>3</sup> The goal here was to modify the DNA with an amino functionality using amino alkoxyamines. The DNA functionalization with aminoxy aminoalkyl dihydrochlorides, **3** and **4**, was investigated using the optimized conditions found for **1**. Unfortunately, in both cases the reaction times were significantly longer and many unidentified side products were obtained. Even when the final concentration of the modifying agents was increased to 1.0 M, full conversion was not obtained after 5 days. The corresponding mono-substituted products were observed, but due to the fact that the reaction results in complex product mixtures, this reaction was not pursued further.

### DNA modification with benzyloxyamines

In light of the results described above, it was decided to focus on aryloxy- and benzyloxyamines. Phenylloxyamine hydrochloride **5** gave no reaction, even after several days. This suggests that this reagent is not sufficiently nucleophilic. In contrast, excellent results were achieved using benzyloxyamine hydrochloride **6**. After 48 h, the reaction had almost reached completion (97% conversion) and the desired mono-substituted product **A** was obtained as the major product with an A/B ratio of 12 : 1 (Table 2, entry 2). Increasing the final concentration of the alkoxyamine, resulted in a lower ratio compared to entry

Table 2 Reaction of oligo **1** with aryl and benzyloxyamines<sup>a</sup>


Entry	Reagent	Conversion <sup>b</sup> (%)	Time <sup>c</sup> (d)	Ratio A/B <sup>d</sup>
1	<b>5</b>	—	3	—
2	<b>6</b>	97	2	12
3	<b>6</b> <sup>e</sup>	90	5	Only A <sup>g</sup>
4	<b>7</b> <sup>f</sup>	98	3	Only A <sup>g</sup>

<sup>a</sup> **5**, M5A/B: R = phenyl  
<sup>b</sup> **6**, M6A/B: R = benzyl  
<sup>c</sup> **7**, M7A/B: R = 4-azidobenzyl

<sup>a</sup> All experiments were carried out with oligo **1** [100 μM] and a final concentration of alkoxyamine reagent of 0.5 M, at pH = 4 and 50 °C, unless noted otherwise. <sup>b</sup> Determined by RP-HPLC. <sup>c</sup> Time after which the samples were taken. <sup>d</sup> Ratio mono/double substituted products, determined by RP-HPLC. <sup>e</sup> Reaction with oligo **2** [100 μM]. <sup>f</sup> Final concentration of compound **7** 0.25 M. <sup>g</sup> Disubstituted product B was not detected.

2. The product was purified by reversed phase-HPLC, giving rise to 12% isolated yield.


The product **M6A** was subjected to an MS/MS analysis to verify that indeed the cytosine had been modified selectively (Fig. S2†). Assignment of the peaks resulting from the small fragments of the product confirmed the presence of unmodified A, G and T nucleobases; no peaks corresponding to any of these bases carrying the benzyloxyamino functionality were found. However, unmodified cytosine fragments were not observed after fragmentation. Instead, a fragment with  $m/z$  = 216.1 was found which corresponds to the benzyloxyamino modified cytosine nucleobase. Moreover, analysis of the larger fragments confirmed that A, T and G were not modified (ESI†). Additionally, the assignment of fragments at  $m/z$  1110.6 and 1279 supports modification at C.

Given the success of modifying oligo **1** with benzyloxyamine hydrochloride a longer sequence of DNA was tested. The reaction with oligo **2** (dAATACGTG) was investigated using the optimized conditions. The reaction was found to be highly selective, *i.e.* the double substituted product could not be detected, but slow (Table 2, entry 3). After 5 days, 90% conversion was obtained, as determined by HPLC. The product was purified by preparative RP-HPLC and its identity was confirmed by MALDI-TOF ( $m/z$  = 2534).

### DNA modification with a bifunctional benzyloxyamine

Having established the efficient and selective modification of DNA with benzyloxyamine, we focused on using the bifunctional benzyloxyamine derivative **7**, carrying an azide moiety that can be used for further functionalization. The reaction was followed by RP-HPLC and analysed by MALDI-TOF. Full conversion was obtained after 3 days at 50 °C. The





**Scheme 4** Click reaction of **M7A**. Conditions:  $\text{CuSO}_4$ : monophos: sodium ascorbate (1 : 1.1 : 10) (5 mol% copper), excess of alkyne.

modification process was highly selective towards the mono-substituted product **M7A**, *i.e.* formation of the disubstituted product **M7B** was not observed. **M7A** was purified by size exclusion chromatography (75–80% yield).

The azide functionality can be reacted further using either the Huisgen 1,3-dipolar cycloaddition.<sup>21</sup> Thus, DNA labelled with an azide moiety is an attractive building block for introducing fluorophores, carbohydrates and ligation to other biomolecules.<sup>22</sup> The copper catalysed azide–alkyne cycloaddition procedure that was applied involves a recently reported copper-monophos catalyst, which has been shown to significantly accelerate the reaction.<sup>23</sup> This procedure is compatible with peptides and enzymes and it can be performed in aqueous media. The reaction was explored using two different alkynes (Scheme 4), phenylacetylene **15** and the fluorescent alkyne **16**, a derivate of dansyl chloride.

Copper(II) sulphate was used as the copper source, which was reduced to Cu(I) *in situ* by sodium ascorbate. The mixture of copper and ligand was added to the solution of the alkyne and azide, under nitrogen atmosphere. The click reactions were followed by reversed phase. Full conversion was achieved within 2 hours in both reactions. The DNA functionalized products, **M8A** and **M9A**, were obtained after preparative HPLC in isolated yields of 14–15% over 2 steps.

## Conclusions

A new method for the selective chemical modification of DNA at cytosine nucleobases using alkoxy- and benzyloxyamines was developed. The most effective modifying agents were found to be benzyloxyamines, which proved to give almost exclusively formation of the mono addition products. By using a bifunctional derivative, that is, *p*-azidobenzyloxyamine hydrochloride, an azide moiety, which is a convenient handle for further functionalization, could be introduced into the

DNA. The azido modified DNA was then further reacted in a copper(I)-monophos catalysed 1,3-dipolar cycloaddition. This illustrates the potential of the presented method for application to site and chemo-selective modification of DNA.

## Experimental

### General remarks

Reagents were purchased from Aldrich or Fluka and they were used as received.  $^1\text{H}$ -NMR and  $^{13}\text{C}$ -NMR spectra were recorded on a Varian AMX400 (400 and 100 MHz) in  $\text{CDCl}_3$ . Reversed phase-HPLC (RP-HPLC) analysis were performed on a Shimadzu LC-10AD VP, Waters Xterra MS C18 column ( $3.0 \times 150$  mm, particle size  $3.5 \mu\text{m}$ ) using a gradient of  $\text{CH}_3\text{CN}/\text{TEAA}$  (triethylammonium acetate) buffer 50 mM pH = 7 at  $40^\circ\text{C}$ . For purification purposes Waters Xterra Prep MS C18 column ( $7.8 \times 150$  mm, particle size  $10 \mu\text{m}$ ) at flow  $1.0 \text{ mL min}^{-1}$  was used. Gradient A (general gradient unless noted otherwise):  $\text{CH}_3\text{CN}/\text{TEAA}$  buffer 50 mM pH = 7; gradient: 05/95 0 to 10 min, to 10/90 at 15 min, to 20/80 at 20 min to 30/70 at 30 min, to 50/50 at 50 min to 70/30 at 65 to 05/95 at 95 min for 15 min. Flow of  $0.5 \text{ mL min}^{-1}$  for analytical runs and flow of  $1.0 \text{ mL min}^{-1}$  for the preparative runs. MALDI-TOF measurements were done on a Voyager-DE Pro apparatus (Matrix:  $20 \mu\text{L}$  of a solution of 2,4,6-trihydroxyacetophenone 0.5 M in EtOH +  $10 \mu\text{L}$  of a solution of ammonium citrate dibasic 0.1 M in double distilled (dd)  $\text{H}_2\text{O}$  +  $2 \mu\text{L}$  sample solution in dd  $\text{H}_2\text{O}$ ). HRMS spectra were recorded on a LTQ XL Orbitrap from Thermo Fisher Scientific. **Oligo 1** (dTACTG) and **oligo 2** (dAA-TACGTG) were obtained from BioTez Berlin. Oligonucleotide concentrations were determined using Nanodrop ND-100 from Thermo Fisher Scientific. Column chromatography was performed on silica gel.

### Synthesis of alkoxy amines

**2-(Decyloxy)isoindoline-1,3-dione (9)**. To a solution of 1-bromodecane **8** (2.2 g, 10.0 mmol) and *N*-hydroxyphthalimide (1.96 g, 12.0 mmol) in 50 mL DMF,  $\text{K}_2\text{CO}_3$  (1.66 g, 12 mmol) was added in two portions. The reaction mixture was allowed to react overnight at room temperature. The solvent was evaporated under reduced pressure. The resulting solid was dissolved in dichloromethane (100 mL) and washed with  $\text{H}_2\text{O}$  (100 mL). After separation, the organic layer was washed with  $\text{H}_2\text{O}$  ( $2 \times 30$  mL) and with brine ( $2 \times 30$  mL). The organic layer was dried over  $\text{MgSO}_4$  and concentrated under pressure to give **9** as white solid (2.54 g, 8.3 mmol, 83% yield)  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.83–7.86 (m, 2H), 7.73–7.75 (m, 2H), 4.19 (t,  $J$  = 6.8 Hz, 2H), 1.79 (m, 2H), 1.45 (m, 2H), 1.19–1.35 (m, 12H), 0.87 (t,  $J$  = 6.6 Hz, 3H).  $^{13}\text{C}$  NMR (101 MHz,  $\text{CDCl}_3$ ):  $\delta$  163.7, 134.4, 129.0, 123.5, 78.6, 31.9, 29.5, 29.46, 29.44, 29.3, 28.1, 25.5, 22.7, 14.1. HRMS (positive mode) ( $m/z$ ) calculated mass for  $\text{C}_{18}\text{H}_{25}\text{N}_1\text{O}_3\text{Na}$  [ $\text{M} + \text{Na}$ ] $^+$  326.17266, found mass 326.17242. mp =  $72\text{--}73^\circ\text{C}$ .

**O-Decylhydroxylamine (10)**. To a solution of **9** (2.12 g, 7.0 mmol) in 30 mL of dichloromethane, hydrazine hydrate





(0.7 mL, 14 mmol) was added drop wise. After stirring overnight, the reaction was quenched with NaOH [1 M]. The organic layer was washed with H<sub>2</sub>O (2 × 30 mL), brine (2 × 30 mL), dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The crude solid was further purified by column chromatography (*n*-hexane : ethyl acetate, 7 : 3) to give **10** as a colorless oil (0.83 g, 4.8 mmol, 69% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.34 (br s, 2H -ONH<sub>2</sub>), 3.65 (t, *J* = 6.7 Hz, 2H), 1.57 (m, 2H), 1.18–1.39 (s, 14H), 0.88 (t, *J* = 6.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 76.3, 32.0, 29.7, 29.6, 29.6, 29.4, 28.4, 26.1, 22.7, 14.5. HRMS (positive mode) (*m/z*) calculated mass for C<sub>10</sub>H<sub>24</sub>NO [M + H]<sup>+</sup> 174.18524, found mass 174.18518.

The product was immediately converted to the corresponding hydrochloride salt by treatment with of HCl [6 M]. After filtration, the white solid was lyophilized.

**1-Azido-4-methylbenzene (12).** Prepared following published procedure.<sup>24</sup> 10 g (92.8 mmol) of *p*-toluidine was dissolved in 46 mL of a solution of H<sub>2</sub>O : HCl (1 : 1) at 0 °C. Sodium nitrite (6.3 g, 92.8 mmol) dissolved in 26 mL of cold H<sub>2</sub>O was added drop wise, followed by drop wise addition of sodium azide (6.1 g, 92.8 mmol) in 58 mL H<sub>2</sub>O. After 1 h CHCl<sub>3</sub> (100 mL) was added. The aqueous phase was extracted twice with CHCl<sub>3</sub> (100 mL). The combined organic layers were washed with H<sub>2</sub>O (2 × 30 mL) and dried over MgSO<sub>4</sub>, concentrated under pressure to give **12** as a brown oil (11.1 g, 79.1 mmol, 85%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.17 (d, *J* = 8.0 Hz, 2H), 6.94 (d, *J* = 8.0 Hz, 2H), 2.35 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 137.1, 134.86, 130.3, 118.7, 20.5.

**1-Azido-4-(bromomethyl)benzene (13).** Prepared following a published procedure.<sup>25</sup> To a solution of 1-azido-4-methylbenzene (**12**) (7.14 g, 53.7 mmol) in benzene 200 mL under a nitrogen atmosphere, *N*-bromosuccinimide (10.51 g, 59 mmol) and AIBN 1.0 g were added. The reaction was heated under reflux for 3 days. The solvent was evaporated under reduced pressure. The resulting solid was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (100 mL). The organic layer was washed with H<sub>2</sub>O (2 × 30 mL) and brine (2 × 30 mL), dried over MgSO<sub>4</sub> and concentrated under reduced pressure to give the crude product which was further purified by column chromatography (petroleum ether) to give **13** as a brown oil (7.8 g, 37.1 mmol, 69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.39 (d, *J* = 12.4 Hz, 2H), 7.01 (d, *J* = 12 Hz, 2H), 4.48 (s, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ = 139.9, 134.2, 130.6, 119.3, 32.9.

**2-((4-Azidobenzyl)oxy)-isoindoline-1,3-dione (14).** To a solution of 1-azido-4-(bromomethyl)benzene **13** (3.4 g, 16 mmol) and *N*-hydroxyphthalimide (3.13 g, 19.2 mmol) in 50 mL DMF, K<sub>2</sub>CO<sub>3</sub> (2.65 g, 19.2 mmol) was added in two portions. The reaction mixture reacted overnight. The solvent was evaporated under reduced pressure. The resulting solid was partitioned in CH<sub>2</sub>Cl<sub>2</sub> (150 mL) and H<sub>2</sub>O (100 mL). The organic layer after isolation, it was washed with brine (2 × 50 mL) and then it was dried over MgSO<sub>4</sub>, concentrated under reduced pressure to give **14** as a brown solid (3.5 g, 12.16 mmol, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.87–7.69 (m, 4H), 7.52 (d, *J* = 7.2 Hz, 2H), 7.02 (d, *J* = 7.4 Hz, 2H), 5.17 (s, 2H). <sup>13</sup>C NMR (101 MHz,

CDCl<sub>3</sub>): δ 163.3, 141.1, 134.5, 131.4, 130.1, 128.6, 123.4, 119.0, 78.8. HRMS (positive mode) (*m/z*) calculated mass for C<sub>15</sub>H<sub>10</sub>N<sub>4</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup> 317.06451, found mass 317.06436 mp = 163–164 °C.

**O-(4-Azidobenzyl) hydroxylamine (15).** To a solution 2-((4-azidobenzyl)oxy)-isoindoline-1,3-dione **14** (3.2 g, 10.9 mmol) in 45 mL of CH<sub>2</sub>Cl<sub>2</sub>, hydrazine hydrate (1.04 mL, 33 mmol) was added drop wise. After stirring overnight the reaction was quenched with NaOH [1 M]. The organic layer was washed with H<sub>2</sub>O (2 × 30 mL) and brine (2 × 30 mL). The organic phase was dried over MgSO<sub>4</sub> and concentrated under reduced pressure to give **15** as yellow-brownish oil (1.1 g, 6.1 mmol, 56%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36 (d, *J* = 8.2 Hz, 2H), 7.03 (d, *J* = 8.0 Hz, 2H), 5.41 (br s, 2H -ONH<sub>2</sub>), 4.65 (s, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 139.7, 134.4, 129.9, 119.0, 77.2. HRMS (positive mode) (*m/z*) calculated mass for C<sub>7</sub>H<sub>9</sub>N<sub>4</sub>O [M + H]<sup>+</sup> 165.07709, found mass 165.07690.

The product was immediately converted to the corresponding hydrochloride salt by treatment with of HCl [6 M]. After filtration, the yellow solid was lyophilized.

## DNA modifications

**Stock solutions of reagents.** The hydrochloride salts (compounds 1–7) were dissolved in double distilled (dd) H<sub>2</sub>O and brought to the desired pH by using NaOH [6 M]. The stock solutions were stored at –20 °C.

The oligonucleotides were dissolved in ddH<sub>2</sub>O (final concentrations of 200 μM). The concentrations of the oligonucleotides were determined from their UV/Vis absorptions at 260 nm (Nanodrop) using the calculated extinction coefficients.

**Modification of oligo 1 with CH<sub>3</sub>ONH<sub>2</sub>·HCl; representative procedure.** 100 μL of oligo **1** was mixed with 100 μL of the desired solution of methoxyamine hydrochloride (for final concentrations see Table 1) at the indicated temperatures for the indicated times. The products were purified by preparative reversed phase HPLC (Xterra column gradient B was used: CH<sub>3</sub>CN/TEAA buffer 50 mM pH = 7; gradient: 05/95 0 to 10 min, to 10/90 at 15 min, to 20/80 at 20 min to 30/70 at 30 min, to 50/50 at 50 min to 70/30 at 65 to 05/95 at 95 min for 15 min); flow of 0.5 mL min<sup>–1</sup> for analytical runs and flow of 1.0 mL min<sup>–1</sup> for the preparative column.) and the pure fractions were lyophilized.

Purity of the samples was evaluated with analytical reversed phase HPLC (gradient A) and the identity was confirmed with MALDI-TOF:

**M1A:** Retention time 33.3 min. MALDI-TOF (*m/z*) found 1507 (calculated 1506).

**M1B:** Retention time 34.2 min. MALDI-TOF (*m/z*) found 1554 (calculated 1553).

**Reaction of oligo 1 with 2.** 100 μL of oligo **1** solution was mixed with the desired volume (for final concentrations, see Table 2) of *O*-decylhydroxylamine hydrochloride **5** ([0.7 M], pH = 4). The reaction was followed by RP-HPLC and purified using a preparative Xterra column. Gradient C was used: CH<sub>3</sub>CN/TEAA buffer 50 mM pH = 7; gradient: 05/95 0 to 10 min, to



35/65 at 40 min, to 70/30 at 50 min to 05/95 at 55 min for 15 min. Flow: 0.5 mL min<sup>-1</sup> for analytical runs and flow of 1.0 mL min<sup>-1</sup> with the preparative column. The product fractions were lyophilized.

**M2A:** Retention time (gradient C) = 35.2 min MALDI-TOF (*m/z*) found 1632; calculated 1632.

**M2B:** Retention time (gradient C) = 40.3 min MALDI-TOF (*m/z*) found 1808; calculated 1805.

**Reaction of oligo 1 with 3 and 4.** 100 µL of **oligo 1** solution was mixed with 100 µL of the solution of the alkoxyamine (3 or 4). Two different stock solutions were prepared ([1 M] and [2 M] solution at pH 4). The reactions were followed by RP-HPLC. The reactions did not reach full conversion and many side products were observed.

**M3A:** MALDI-TOF (*m/z*) 1537; calculated 1535.

**M4A:** MALDI-TOF (*m/z*) 1567; calculated 1563.

**M6A/B: reaction of oligo 1 with benzyloxyamine hydrochloride (6).** 500 µL of the stock solution of **oligo 1** was mixed with 500 µL of the freshly prepared solution of **6** [1.0 M] at pH = 4, 50 °C. The reaction was followed by RP-HPLC and the products were purified by preparative RP-HPLC.

**M6A:** Retention time 40.2 min. MALDI-TOF (*m/z*) 1585; calculated 1582 (yield 12%).

**M6B:** Retention time 50.2 min. MALDI-TOF (*m/z*) 1706; calculated 1705 (yield 2%).

**Reaction of oligo 2 with benzyloxyamine hydrochloride (6).** To 200 µL of oligo 2 [200 µM] was added 200 µL of the stock solution of alkoxyamine **6** [1.0 M], pH = 4). The reaction reached 90% conversion after 5 days. The product was analyzed and purified by RP-HPLC.

Retention time = 44.0 min MALDI-TOF (*m/z*) 2534; calculated 2538 (yield 10%).

**M7A: reaction of oligo 1 with *p*-azidobenzyloxyamine hydrochloride (7).** 500 µL of the stock solution of **7** [0.5 M], pH = 4) was added to 500 µL of the **oligo 1** stock solution. The reaction was followed by RP-HPLC and almost complete conversion (98%) was achieved after 3 days. The product was purified by size exclusion chromatography (Sephadex G 15, eluting with TEAA buffer) and lyophilized to give **M7A**.

**M7A:** Retention time 43.5 min MALDI-TOF (*m/z*) 1624; calculated 1623.

### General procedure for click reaction

Before use, all the solutions were flushed with nitrogen for 10–15 min. The azido-modified **M7A** was dissolved in 600 µL of ddH<sub>2</sub>O.

The catalyst solution was prepared by dissolving CuSO<sub>4</sub>·5H<sub>2</sub>O (2.5 mg, 0.01 mmol) and sodium ascorbate (19.8 mg, 0.1 mmol) in 1.5 mL of ddH<sub>2</sub>O, followed by addition of monophos (4.1 mg) in 500 µL of DMSO. This solution was allowed to stir for 10–15 min and then used in the click reaction.

**M8A.** 100 µL (0.91 mmol) of phenylacetylene (**15**) was dissolved in 500 µL of DMSO. 100 µL of this solution was added to the DNA solution and after stirring for 5 min, 125 µL of the Cu(I) catalyst solution was added. The reaction was stirred for

2 h at room temperature. The mixture was lyophilized and then purified by preparative reversed phase HPLC using gradient A, to give **M8A** (retention time = 50.5 min) in 15% yield after 2 steps. MALDI-TOF (*m/z*) 1726; calculated 1725.


**M9A.** 2 mg (0.007 mmol) of the alkyne modified dansyl derivative **16** was dissolved in 100 µL of DMSO. 100 µL of the solution of the alkyne was added to the DNA and after 5 min of stirring together, 125 µL of the Cu(I) catalyst solution was added. The reaction was stirred for 2 h at room temperature and was then lyophilized. Purification by preparative RP-HPLC using gradient A (retention time = 53.0 min) furnished **M9A** in a yield of 14% over 2 steps. MALDI-TOF (*m/z*) 1917; calculated 1911.

## Acknowledgements

The authors thank the European Research Council (ERC starting grant no. 280010) and the Ubbo Emmius Foundation for financial support. G.R. gratefully acknowledges support from the Ministry of Education, Culture and Science (Gravitation program 024.001.035). Dr W. Szymanski is thanked for kindly providing the dansyl derivative **16**.

## Notes and references

- (a) T. J. Bandy, A. Brewer, J. R. Burns, G. Marth, T. N. Nguyen and E. Stulz, *Chem. Soc. Rev.*, 2011, **40**, 138; (b) P. W. K. Rothmund, *Nature*, 2006, **440**, 297; (c) N. C. Seeman, *Nature*, 2003, **421**, 427.
- M. Hocek and M. Fojta, *Chem. Soc. Rev.*, 2011, **40**, 5802.
- S. H. Weisbrod and A. Marx, *Chem. Commun.*, 2008, 5675.
- (a) N. Sancho Oltra and G. Roelfes, *Chem. Commun.*, 2008, 6039; (b) L. Gjonaj and G. Roelfes, *ChemCatChem*, 2013, **5**, 1718.
- M. Kwak and A. Herrmann, *Chem. Soc. Rev.*, 2011, **40**, 5745.
- (a) S. L. Beaucage and R. P. Iyer, *Tetrahedron*, 1993, **49**, 1925; (b) C. B. Reese, *Org. Biomol. Chem.*, 2005, **3**, 2851; (c) A. H. El-Sagheer and T. Brown, *Acc. Chem. Res.*, 2012, **45**, 1258.
- (a) M. Hocek and M. Fojta, *Org. Biomol. Chem.*, 2008, **6**, 2233; (b) R. Kranaster and A. Marx, *ChemBioChem*, 2010, **11**, 2077.
- S. Klimašauskas and E. Weinhold, *Trends Biotechnol.*, 2007, **25**, 99.
- (a) G. Pljevaljcic, F. Schmidt and E. Weinhold, *ChemBioChem*, 2004, **5**, 265; (b) Z. Liutkevičiūtė, E. Kriukiene, I. Grigaityte, V. Masevičius and S. Klimašauskas, *Angew. Chem., Int. Ed.*, 2011, **123**, 2138.
- C. Song and C. He, *Acc. Chem. Res.*, 2011, **44**, 709.
- M. Di Antonio, F. Doria, S. N. Richter, C. Bertipaglia, M. Mella, C. Sissi, M. Palumbo and M. Freccero, *J. Am. Chem. Soc.*, 2009, **131**, 13132.



- 12 G. M. Blackburn, M. J. Gait, D. Loakes and D. M. Williams, in *Nucleic acids in Chemistry and Biology*, RSC, Cambridge, 3rd edn, 2006, ch. 8, pp. 302–303.
- 13 (a) K. Tishinov, K. Schmidt, D. Häussinger and D. G. Gillingham, *Angew. Chem., Int. Ed.*, 2012, **51**, 12000; (b) K. Tishinov, N. Fei and D. Gillingham, *Chem. Sci.*, 2013, **4**, 4401.
- 14 (a) P. de Hoog, C. Boldron, P. Gamez, K. Slidregt-Bol, I. Roland, M. Pitié, R. Kiss, B. Meunier and J. Reedijk, *J. Med. Chem.*, 2007, **50**, 3148; (b) P. de Hoog, P. M. Pitié, G. Amedei, P. Gamez, B. Meunier, R. Kiss and J. Reedijk, *J. Biol. Inorg. Chem.*, 2008, **13**, 575; (c) Ş. Özalp-Yaman, P. de Hoog, G. Amedei, P. M. Pitié, P. Gamez, J. Dewelle, T. Mijatovic, B. Meunier, R. Kiss and J. Reedijk, *Chem. – Eur. J.*, 2008, **14**, 3418.
- 15 (a) M. Villien, S. Deroo, E. Gicquel, E. Defrancq, C. Moucheron, A. Kirsch-DeMesmaeker and P. Dumy, *Tetrahedron*, 2007, **63**, 11299; (b) N. Tuccitto, N. Giamblanco, S. Ghosh, V. Spampinato, P. Labbé, P. Dumy, S. Quici, G. Marletta, E. Defrancq and A. Liccardello, *Langmuir*, 2011, **27**, 8595; (c) P. Crisalli, A. R. Hernández and E. T. Kool, *Bioconjugate Chem.*, 2012, **23**, 1969.
- 16 A. M. Maxam and W. Gilbert, *Proc. Natl. Acad. Sci. U. S. A.*, 1977, **74**, 560.
- 17 B. H. Johnston, *Methods Enzymol.*, 1992, **212**, 180.
- 18 (a) C. Nagata and O. Mårtensson, *J. Theor. Biol.*, 1968, **19**, 133; (b) E. I. Budowsky, E. D. Sverdlov and T. N. Spasokukotskaya, *Biochim. Biophys. Acta*, 1972, **287**, 195.
- 19 M. C. Pankaskie and S. A. Stolz, *Synth. Commun.*, 1989, **19**, 339.
- 20 (a) M. Langecker, V. Arnaut, T. G. Martin, J. List, S. Renner, M. Mayer, H. Dietz and F. C. Simmel, *Science*, 2012, **338**, 932; (b) Y. H. Roh, J. B. Lee, P. Kiatwuthinon, M. R. Hartman, J. J. Cha, S. H. Um, D. A. Miller and D. Luo, *Small*, 2011, **7**, 74; (c) F. E. Alemdaroglu, N. C. Alemdaroglu, P. Langguth and A. Herrmann, *Adv. Mater.*, 2008, **20**, 899.
- 21 R. Huisgen, in *1,3-Dipolar Cycloaddition Chemistry*, ed. A. Padwa, Wiley, New York, 1984, p. 1.
- 22 A. H. El-Sagheer and T. D. Brown, *Chem. Soc. Rev.*, 2010, **39**, 1388.
- 23 L. S. Campbell-Verduyn, L. Mirfeizi, R. A. Dierckx, P. H. Elsinga and B. L. Feringa, *Chem. Commun.*, 2009, 2139.
- 24 M. T. Klapötke, B. Krumm, H. Piotrowski, K. Polborn and G. Holl, *Chem. – Eur. J.*, 2003, **9**, 687.
- 25 W. Trommer and M. Hendrick, *Synthesis*, 1973, 484.

